BCL2 and plasma cell myeloma: Third, future clinical trials should additionally focus on the incorporation of BCL2 inhibitors into earlier treatment lines, and potent combinations of BCL2 inhibitors in conjunction with other anti-myeloma agents and novel intervention strategies hold the potential to enhance the outcome in both patients with NDMM and patients with RRMM.